Adebelimab Combined with Apatinib for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Jan 2025: Trial registered, NCT06771154

The trials

NCT06771154: Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial

State
Not started
Phase
Phase 2
People
140 planned
Started
1 Apr 2025
Primary completion
1 Apr 2029
Arms
Maintenance Therapy Group with Adebrelimab Combined with Apatinib
Results
None posted
  1. 13 Jan 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.